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Summary
Background Although people with serious mental illnesses have a high risk of contracting blood-borne viral infections, 
sexual health has largely been neglected by researchers and policy makers involved in mental health. Failure to 
address this shortcoming could increase morbidity and mortality as a result of undetected and untreated infection. 
We did a systematic review and meta-analysis to estimate the prevalence of blood-borne viral infection in people with 
serious mental illness.
Method We searched the Cochrane Library, Medline, Embase, PsycInfo, CINAHL, and DARE for studies of the 
prevalence of HIV, hepatitis B virus, and hepatitis C virus in people with serious mental illness, published between 
Jan 1, 1980, and Jan 1, 2015. We group prevalence data by region and by virus and estimated pooled prevalence. We did 
a sensitivity analysis of the eﬀ ect of study quality on prevalence.
Findings After removal of duplicates, we found 373 abstracts, 91 of which met our eligibility criteria. The prevalences 
of blood-borne viral infections in people with serious mental illness were higher than in the general population in 
places with low prevalence of blood-borne viruses, such as the USA and Europe, and on par with the general 
population in regions with high prevalence of blood-borne viruses (Africa for HIV and southeast Asia for hepatitis B 
virus and hepatitis C virus). Pooled prevalence of HIV in people with serious mental illness in the USA was 6·0% 
(95% CI 4·3–8·3). Sensitivity analysis showed that quality scores did not signiﬁ cantly aﬀ ect prevalence.
Interpretation People with serious mental illness are at risk of blood-borne viral infections. However, because of 
methodological l imitations of the studies the prevalence might be overestimated. Serious mental illness is unlikely to 
be a sole risk factor and risk of blood-borne viral infection is probably multifactorial and associated with low 
socioeconomic status, drug and alcohol misuse, ethnic origin, and sex. Health providers should routinely discuss 
sexual health and risks for blood-borne viruses (including risks related to drug misuse) with people who have serious 
mental illness, as well as oﬀ ering testing and treatment for those at risk.
Funding Wellcome Trust.
Copyright © Hughes et al. Open Access article distributed under the terms of CC BY.
Introduction 
240 million people have a serious mental illness, with a 
broadly similar distribution worldwide.1 Serious mental 
illness is deﬁ ned as a diagnosis of mental illness (eg, 
schizophrenia and schizoaﬀ ective disorders, bipolar 
disorder, or psychosis) that is persistent, disabling, and 
requiring specialised psychiatric treatment as an 
outpatient or inpatient admission.1 The point prevalence 
of serious mental illness is 4·6 cases per 1000 people, 
and 4·0% of people have a serious mental illness at some 
point during their life.1
With the increasing evidence that people with serious 
mental illness have signiﬁ cant health inequalities,2 
increasing prominence has been given to physical health 
screening, health education, and improving access to 
treatment in primary and secondary care. However, 
sexual health needs, including screening for and 
prevention of sexually transmitted infections and blood-
borne viruses, are neglected in this population. Of 
particular concern is the higher risk of blood-borne virus 
infections (HIV, hepatitis B virus, and hepatitis C virus), 
shown by prevalence studies done over the past 30 years.3,4 
These viruses are transmitted by parenteral contact with 
contaminated body ﬂ uids (blood and blood products; 
contaminated instruments and needles; semen and 
vaginal ﬂ uids). Transmission can also occur through 
unprotected sex (anal, vaginal, or oral), vertical 
transmission from mother to baby, and by sharing drug 
injecting equipment.
HIV, hepatitis B, and hepatitis C are serious infections, 
but can be treated. The prognosis is much improved by 
earlier detection and treatment. Prevalence studies3,5,6 
have shown that serious mental illness is a risk factor 
for blood-borne virus infection. Many people with 
serious mental health problems engage in behaviours 
that increase their risk of infection with blood-borne 
viruses, including unprotected sex with multiple 
partners, sex work (or sex trading—performing sexual 
acts in exchange for a commodity), and intravenous 
drug use (or having a sexual partner who is an injecting 
drug user). Further risk can result from hypersexuality 
during an acute phase of mental illness, as well as 
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co-occurring substance misuse problems that can lead 
to sexual risks while intoxicated. Finally, people with 
serious mental illness who live in shared accommodation 
might share personal equipment (eg, razors, 
toothbrushes), which might increase the risk of 
hepatitis B and hepatitis C transmission.
In the UK, 93 000 men and 40 000 women are infected 
with HIV, and in 2013, there were 6000 new cases of 
HIV.7 In 2012, the incidence of hepatitis B in England 
was 1·4 cases per 100 000 people per year and prevalence 
was 0·1–0·5%.8 In 2009, the overall incidence of reported 
acute hepatitis B in the USA9 was 1·5 per 100 000 people 
per year and 800 000–1·4 million people in the USA have 
chronic hepatitis B virus infection. 786 000 people 
worldwide die from hepatitis B virus-related liver disease 
each year.10,11 About 3% of the world’s population are 
infected with hepatitis C virus, with about 4 million 
carriers in Europe alone12 and 214 000 in the UK.10 There 
were 17 000 new cases of hepatitis C in the USA in 2007, 
with 3·2 million people infected in total.
Although previous reviews of blood-borne infection in 
people with serious mental illness have been published,3,5,6 
no systematic reviews have been done and the reviews 
rarely reported the rate of HIV, hepatitis B, and 
hepatitis C.13 We did a systematic review and meta-
analysis of prevalence studies to understand the global 
prevalence of HIV, hepatitis B virus, and hepatitis C virus 
in people with serious mental illness.
Methods
Search strategy
We searched the Cochrane Library, Medline, Embase, 
PsycInfo, CINAHL, and DARE for studies published in 
English between Jan 1, 1980, and June 5, 2012, with the 
terms “hepatitis C”, ‘HCV’, “hepatitis B”, ‘HBV’, “HIV”, 
“human immunodeﬁ ciency virus”, “blood borne virus” 
cross-referenced with “bipolar”, “psychiatr*”, 
“schizophreni*”, “psychosis”, “schizoaﬀ ective”, “mental 
patient*”, “mental illness”, and “mental disorder*”. We 
also included eligible studies cited in reports identiﬁ ed 
by our database search. We repeated the search for June 
5, 2012, to Jan 1, 2015, and identiﬁ ed two more papers.
Data collection
We systematically searched the scientiﬁ c literature for 
observational cross-sectional studies that reported the 
seroprevalence of HIV, hepatitis B virus, or hepatitis C 
virus according to opt-in, opt-out, or anonymous unlinked 
blood or other bodily ﬂ uids research methods, in people 
aged older than 15 years, diagnosed with serious mental 
illness, and treated in a psychiatric setting. We excluded 
studies in which prevalence data were only obtained from 
case notes or only from self-report (not independently 
veriﬁ ed by testing). We did not include grey literature.
After removing duplicates, SB screened the titles and 
abstracts using the eligibility criteria, with independent 
veriﬁ cation by EH and FM. For studies deemed suitable, 
we obtained the full text and they were again scrutinised 
against the eligibility criteria by SB and veriﬁ ed 
independently by EH and FM. Reports about which there 
was uncertainty were discussed by FM and EH with SB 
until a consensus about eligibility was achieved. We 
extracted data from eligible full-text articles including 
Figure 1: Study selection
373 reports identiﬁed through 
 database search
204 reports screened for 
 eligibility
91 studies analysed
169 duplicates excluded
89 full-text articles assessed for 
 eligibility
2 studies identiﬁed from an 
 updated search
115 ineligible
Date Location Number of 
participants
Prevalence of 
HIV (%)
Quality 
score
North America
Clair et al15 1989 USA 1496 0·24 1
Hatem et al16 1990 USA 163 1·8 1
Cournos et al17 1991 USA 451 5·5 3
Volavka et al18 1991 USA 515 8·9 3
Lee et al19 1992 USA 135 16·3 0
Sacks et al20 1992 USA 87 3·4 1
Empﬁ eld et al21 1993 USA 203 6·4 2
Meyer et al22 1993 USA 199 4 2
Meyer et al23 1993 USA 87 5·75 1
Susser et al24 1993 USA 62 19·4 1
Stewart et al25 1994 USA 533 5·8 3
Cournos et al26 1994 USA 971 5·2 3
Silberstein et al27 1994 USA 118 22·9 2
Schwartz-Watts et al28 1995 USA 220 5·50 3
Doyle et al29 1997 USA 246 0 1
Krakow et al30 1998 USA 113 19 0
Klinkenberg et al31 2003 USA 204 6·2 2
Rosenberg et al32 2005 USA 755 3 3
Rothbard et al33 2009 USA 588 10 2
Jackson-Malik et al34 2011 USA 64 3·1 1
Himelhoch et al35 2011 USA 153 6·1 2
Europe
Porta et al36 1990 Spain 139 0 0
Naber et al37 1994 Germany 623 4·8 1
Ayuso-Mateos et al38 1997 Spain 390 5·1 3
De Hert et al39 2009 Belgium 595 0·5 2
Kakisi et al40 2009 Greece 805 1 1
(Table 1 continues on next page)
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study characteristics, study date, publication date, 
location, diagnostic criteria, demographics (age, sex, 
ethnicity), consent, consent rate, ethics approval, post-
test treatment, sample size, testing procedure, and 
prevalence.
We used the Quality Assessment Tool for Systematic 
Reviews of Observational Studies to assess the quality of 
the data.14 This instrument is reliable compared with 
other quality assessment tools.14 We modiﬁ ed the tool 
and each report was scored as follows: whether 
participants were clearly deﬁ ned as representing the 
serious mental illness population (yes=1, no=0); 
participation rate (response rate >60%=1, response rate 
≤60% or not reported=0); whether investigators 
controlled for confounding (eg, stratiﬁ cation, matching, 
restriction, adjustment) when analysing associations 
(controlled=1, only descriptive=0); and sample size 
(≥200 participants=1, <200 participants=0).
Data analysis
We did a meta-analysis to calculate combined estimates 
and 95% CIs for each continent separately. We did logistic 
regression to allow for the diﬃ  culties caused by 
proportions being unable to have values less than 0. We 
assumed random eﬀ ects because there was clear clinical 
heterogeneity between the populations sampled. We did 
the calculations using Comprehensive Meta-Analysis 2. 
We transformed logits of estimated prevalence and their 
95% CIs back to percentages. We prepared forest plots 
using Stata (version 12). We calculated relative weights for 
each continent, so that the weights for each continent 
sum to 100.
We did a sensitivity analysis relating to quality scores 
using Stata 13. The outcome variable was the logit-
transformation of prevalence. We did two such analyses: 
one for all studies with quality score as a quantitative 
predictor, and one for all studies using quality score as a 
quantitative predictor and region as a qualitative 
predictor. The results are presented as odds ratio (OR) 
per unit increase in quality score with 95% CIs.
Results
Our literature search identiﬁ ed 373 reports, 169 of which 
were duplicates (ﬁ gure 1). 41 publications were excluded 
because the full text was not available in English, followed 
by another 74 that were ineligible. With the addition of 
two papers from an updated search, we had 91 articles for 
quality assessment and meta-analysis.
44 studies assessed HIV infection (table 1), including a 
total of 21 071 patients. The pooled prevalence of HIV was 
highest in Africa (19%, 95% CI 14–25) and it was 2% in 
Europe and 6% in the USA (tables 1, 2, ﬁ gure 2). Few 
data were available from Europe, Central and South 
America, and Asia, and the prevalence of HIV was very 
poorly recorded in these regions. Only three studies were 
done in India,51,53 and only one study,38 done more than 
20 years ago, was from Spain.
19 studies reported prevalence of hepatitis B virus,53,57,59–62 
including a total of 8163 patients with serious mental 
illness tested for hepatitis B virus (table 3). The pooled 
prevalence of hepatitis B virus was 2·2% (95% CI 
0·5–9·9) in North America, and 9·7% (95% CI 0·6–15·3) 
in Asia (table 2, ﬁ gure 3). A study from Turkey60 reported 
51% hepatitis B virus prevalence with 10% HBsAg 
positivity indicating active infection; the virus is highly 
prevalent in the general population of Turkey. A study 
from Taiwan61 reported an 18% prevalence of HBsAg, 
which is consistent with the general population: 
hepatitis B virus infection is endemic in Taiwan, with 
80–90% of adults infected.
Date Location Number of 
participants
Prevalence of 
HIV (%)
Quality 
score
(Continued from previous page)
Africa
Acuda et al41 1996 Zimbabwe 143 23·8 2
Mashaphu et al42 2007 South Africa 63 23·8 1
Collins et al43 2009 South Africa 151 26·5 3
Singh et al44 2009 South Africa 206 29·1 3
Omoregie et al45 2009 Nigeria 121 15·5 1
Henning et al46 2011 South Africa 195 12 2
Maling et al47 2011 Uganda 272 18·4 4
Lundberg et al48 2013 Uganda 602 11·3 4
Asia
Dasananjali49 1994 Thailand 325 1·85 2
Chandra et al50 2003 India 2283 2·11 1
Tharyan et al51 2003 India 1160 1·03 3
Chen52 1994 Taiwan 834 0 2
Carey et al53 2007 India 948 1·7 4
Central and South America
Rodgers-Johnson et al54 1996 Jamaica 201 2·5 2
Hutchinson et al55 1999 Trinidad 
and Tobago
1227 6·9 1
Alvarado-Esquivel et al56 2008 Mexico 105 0·9 0
Guimarães et al57 2009 Brazil 2238 0·8 3
Gibson et al58 2010 West Indies 82 7·3 1
Table 1: Included studies of HIV in people with serious mental illness
HIV Hepatitis B virus Hepatitis C virus
Studies 
(n)
Prevalence (95% CI) Studies 
(n)
Prevalence (95% CI) Studies 
(n)
Prevalence (95% CI)
North 
America
21 6·0% (4·3–8·3) 2 2·2% (0·5–9·9) 13 17·4% (13·2–22·6)
Europe 5 1·9% (0·8–4·8) 4 2·7% (1·8–3·9) 6 4·9% (3·0–7·9)
Oceania 0 ·· 0 ·· 1 3·1% (1·0–9·3)
Africa 8 19·2% (14·4–25·2) 0 ·· 0 ··
Asia 5 1·5% (1·0–2·4) 10 9·7% (0·6–15·3) 7 4·4% (2·8–6·9)
Central 
and South 
America
5 2·7% (0·8–8·2) 3 2·6% (1·0–6·1) 2 3·0% (1·8–5·0)
Table 2: Pooled prevalence in people with serious mental illness
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28 studies tested 14 888 patients with serious mental 
illness for hepatitis C virus (tables 2, 4, ﬁ gure 4). The 
prevalence of hepatitis C in people with serious mental 
illness was greatest in Turkey, perhaps a result of the 
high prevalence in the general population in Turkey. 
Pooled data from 13 studies from North America gave a 
prevalence of 17·4% (95% CI 13·2–22·6), which is 
higher than in the general population, of whom roughly 
1% are infected (2·7 million).88 In Asia, pooled hepatitis 
C virus prevalence was 4·4% (95% CI 2·8–6·9). 
However, these data are from large and diverse 
geographical areas including southeast Asia and Turkey.
Most studies consisted of convenience samples of 
people recruited from a particular treatment setting, 
typically inpatient psychiatric care. Although all the 
studies included patients with serious mental illness, the 
proportions of speciﬁ c diagnoses in each sample varied. 
We assessed the eﬀ ect of study quality on virus prevalence 
by meta-regression on quality score, for all studies 
combined and adjusting for geographical region. No 
analysis showed a signiﬁ cant eﬀ ect of study quality on 
prevalence (table 5).
Most of the studies had additional data on risk factors 
for blood-borne viruses, such as intravenous drug use 
and sexual behaviour, to test associations with infection. 
The reporting and the nature of these risk factors varied 
widely. Infomation on risk factors was mainly extracted 
from routine clinical case notes as opposed to using a 
standardised risk tool.89 Because of the variability of 
data quality and reporting consistency, we could not 
calculate adjusted prevalence after controlling for these 
risk factors. However, three common factors seem to 
increase the likelihood of infection with a blood-borne 
virus: ﬁ rst, being black and female;17,26 second, injecting 
drug use;32 and third, engaging in risky sexual 
behaviour, including not using a condom, having 
multiple partners, sex trading, and unprotected sex 
with a partner who is infected with a blood-borne virus.
Discussion
Our aim was to estimate the prevalence of blood-borne 
infection in people with serious mental illness. Most of 
the studies were of moderate to low quality, and based on 
convenience samples drawn from treatment settings 
rather than representative samples. This sampling 
method means that the prevalence reported was possibly 
overestimated. However, a study in Brazil, which used a 
representative sample drawn from the community as 
well as treatment settings, still showed that blood-borne 
infections are common in people with serious mental 
illness.57 The quality of deﬁ ning the sample in terms of 
diagnoses of mental illness varied. Many studies used 
case note diagnoses rather than independently veriﬁ ed 
diagnoses made with gold standard diagnostic tools. 
Inpatient settings are likely to treat the most acutely ill 
people often with complex needs and a history of 
substance misuse.
The prevalences of blood-borne viruses in people with 
serious mental illness were consistently higher than in 
the general population in regions with a low prevalence 
of blood-borne viruses, such as North America and 
Europe, and on par with the general population in 
regions with high general prevalence such as Africa for 
HIV and southeast Asia for hepatitis B virus and 
hepatitis C virus. The estimated prevalence of HIV in 
Figure 2: Prevalence of HIV in people with serious mental illness
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Date Location Number 
of 
patients
HbAg 
(%)
Quality 
score
North America
Tabibian et al63 2008 USA 129 0·78 1
Wise et al64 2012 USA 115 4 2
Europe
Gmelin et al65 1982 Germany 714 2·38 1
Porta et al36 1990 Spain 139 2·3 0
Di Nardo et al66 1995 Italy 206 4·8 1
Kakisi et al40 2009 Greece 805 2 1
Asia
Tey et al67 1987 Singapore 71 12·7 1
Chaudhury et al68 1993 India 60 10 1
Chang et al61 1993 Taiwan 780 18·1 1
Chaudhury et al69 1994 India 100 11 1
Kimhi et al70 1997 Israel 121 32 0
Said et al71 2001 Jordan 192 7·29 1
Kuloglu et al60 2006 Turkey 255 10·1 3
Carey et al53 2007 India 948 3 4
Mamani et al72 2009 Iran 170 1·2 1
Hung et al12 2012 Taiwan 588 10·4 3
Central and South America
de Souza et al73 2003 Brazil 433 1·6 3
Alvarado Esquivel et al59 2005 Mexico 99 7·1 3
Guimarães et al57 2009 Brazil 2238 1·6 3
Table 3: Included studies of hepatitis B
people with serious mental illness in the USA was 6% 
(95% CI 4·3–8·3), which is considerably higher than 
the 0·6% of the general population of the USA who 
have HIV.90
However, serious mental illness might not be an 
isolated risk factor for blood-borne virus infection, but 
might be better thought of as a potentially confounded 
association with poor socioeconomic background, drug 
and alcohol misuse, sex, and ethnic origin.
Three USA studies18,21,26  included odds ratios adjusted 
for risk factors and showed that they signiﬁ cantly 
increased the risk of HIV and other blood-borne viral 
infections. However, these studies were done in settings 
where dual diagnosis of substance misuse and mental 
illness is very common. The samples were drawn from 
psychiatric inpatient and outpatient services in deprived 
urban areas with substantial social deprivation and 
health inequality, especially in those of non-white ethnic 
backgrounds.
Several studies, from both high prevalence and low 
prevalence locations, individually found a positive 
association between sex and infection. Women had a 
signiﬁ cantly higher risk of HIV infection than did men 
drawn from the same populations. One explanation 
might be that women with serious mental illness are 
more likely to experience exploitation and sexual assault, 
as well as power diﬀ erentials, making them less 
empowered to negotiate condom use or to refuse sex.91 By 
contrast, men with serious mental illness were more 
likely to carry hepatitis B virus or hepatitis C virus, which 
could be because injecting drug use is more common in 
men. However, the causes of these sex diﬀ erences were 
probably multifactorial, which we could not assess 
because of the heterogeneity of geography, demographics, 
and risk factors in the studies we included.
Many of the studies have been done in the USA, with 
fewer located in other countries. Of particular note is the 
paucity of research in Europe, and there have been no 
prevalence studies done in the UK. However, two articles 
suggest a potential problem in the UK. A hepatitis C 
virus screening and referral project done by an assertive 
outreach mental health team92 showed more than 
expected infections amongst users of the service. Of 
76 users, ten (13%) were hepatitis C virus positive, and 
almost half had a history of intravenous drug use. 
Another article93 reported on the acceptability and 
feasibility of oﬀ ering testing for blood-borne viruses in 
psychiatric inpatient settings. The results suggest more 
HIV, hepatitis B virus, and hepatitis C virus in patients 
who participated in the study. Overall, 18% of participants 
had current or past exposure to a blood-borne virus, one 
of whom was newly diagnosed with HIV and three were 
newly diagnosed with hepatitis B virus. Therefore, there 
is an urgent need to undertake high quality 
epidemiological studies of blood-borne virus infections 
and their associated risk behaviours in the people with 
serious mental illness in the UK and northern Europe.Figure 3: Prevalence of hepatitis B virus in people with serious mental illness
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Year Location Number of 
patients
Hepatitis C 
virus (%)
Quality 
score
North America
Al Jurdi et al74 2003 USA 238 16 3
Klinkenberg et al31 2003 USA 204 30 2
Osher et al75 2003 USA 668 18 3
Dinwiddie et al76 2003 USA 1556 8·5 3
Butterﬁ eld et al77 2003 USA 376 18·9 2
Rosenberg et al32 2005 USA 755 14 3
Freudenreich et al78 2007 USA 98 8·2 2
Tabibian et al63 2008 USA 129 38 1
Goldberg et al79 2008 USA 100 31 1
Matthews et al80 2008 USA 112 12 0
Rothbard et al33 2009 USA 588 21 2
Sockalingam et al81 2010 Canada 110 2·7 1
Himelhoch et al35 2011 USA 153 24·8 1
Europe
Di Nardo et al66 1995 Italy 206 10·7 1
Cividini et al82 1997 Italy 1180 6·7 2
Stroﬀ olini et al83 2003 Italy 526 5·1 1
Raja et al84 2006 Italy 1492 2·8 3
De Hert et al39 2009 Belgium 595 0·7 2
Kakisi et al40 2009 Greece 805 9 1
Central and South America
Alvarado-Esquivel et al56 2008 Mexico 99 4·8 0
Guimarães et al57 2009 Brazil 2238 2·63 3
Oceania
Gunewardene et al85 2010 Australia 95 3·1 1
Asia
Chang et al61 1993 Taiwan 780 6·8 3
Kimhi et al70 1997 Israel 121 4·13 0
Sawayama et al86 2000 Japan 196 10·2 2
Nakamura et al87 2004 Japan 455 6·15 3
Kuloglu et al60 2006 Turkey 255 2·7 3
Mamani et al72 2009 Iran 170 1·8 1
Hung et al12 2012 Taiwan 588 1·9 3
Table 4: Included studies of hepatitis C virus in people with serious mental illness
Few studies systematically collected data for risk factors 
directly from the participants. The risk data were mainly 
collected from case notes and routine clinical record 
systems. Sexual and drug use behaviours are probably 
under-reported in case notes, because there is evidence 
that mental health services do not consistently assess 
these behaviours in routine care.94,95 Without accurate 
and consistent measurement of risks, we could not 
calculate the eﬀ ect of the risk factors as mediators of 
infection in this population, and have merely mentioned 
the factors identiﬁ ed by individual studies that warrant 
more rigorous investigation. There is a need for a 
prospective longitudinal study of a cohort of people with 
serious mental illness, which can track risk behaviour 
and infections powered suﬃ  ciently to identify the 
mediating factors between serious mental illness and 
blood-borne virus infection.
We included cross-sectional studies. None of the 
studies included a matched comparison group of people 
without serious mental illness. Prospective cohort 
studies are needed that use representative samples 
alongside matched controls of people without serious 
mental illness. Such studies are the only way to 
accurately test whether the prevalence of blood-borne 
viruses is signiﬁ cantly elevated in people with serious 
mental illness compared with the general population. 
Comparing the estimated prevalence with available data 
for the country or region is limited but it does oﬀ er some 
indication that prevalence is higher in people with 
serious mental illness. The prevalence of HIV infection 
in the general population is much lower in the UK96 than 
in the USA, and therefore the assumption is that HIV 
infection is less of a risk for people with serious mental 
illness who live in the UK. However, hepatitis C virus is 
prevalent in drug users in the UK,97 and there could be a 
risk of hepatitis C virus infection and co-infections in 
people with serious mental illness as a result of 
substance misuse.98
This meta-analysis estimated pooled prevalence of 
HIV, hepatitis B virus, and hepatitis C virus in people 
with serious mental illness. Our review included only 
published work, and therefore might have missed 
studies yet to be reported. In addition, the search 
strategy included only reports published in English, 
which might have biased our ﬁ ndings towards English-
speaking countries.
It is unclear why sexual health has been neglected as 
part of the physical health agenda for people with serious 
mental illness. One reason might be the perception that 
people with serious mental illness do not engage in 
activities that place them at risk, such as intravenous 
drug use or unprotected sex. However, 30–50% of people 
with serious mental illness have substance misuse 
disorders,98,99 and, although intravenous drug use is rare, 
patients might have sexual partners who inject drugs, 
facilitating viral transmission. Additionally, as with the 
population as a whole, a substantial proportion of people 
with serious mental illness are sexually active and see 
intimate relationships as an important part of their 
lives.5,100 The lack of attention of policy makers and 
educators has led to a lack of awareness and a failure to 
provide people with serious mental illness with access to 
assessment, screening, and education for sexually 
transmitted infections, including blood-borne viruses.
A qualitative study in London101 documented that most 
people with psychosis were engaged in seeking and 
forming intimate relationships. Additionally, some had 
negative and harmful relationship experiences, including 
sexual exploitation and violence, yet these issues were 
rarely part of their routine consultation with their health-
care providers. This lack of attention to sexual health and 
safety has also been reported in a review,91 which found 
that although women with serious mental illness were 
twice as likely to be exposed to severe domestic violence 
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compared with women in the general population, these 
incidents were rarely detected by the health-care services 
they attended. A survey of psychiatrists in a Sydney, 
Australia, mental health service102 found poor knowledge 
of hepatitis C virus, and clinicians perceived their 
patients to be at lower risk than prevalence studies 
suggest.3 A survey of mental health staﬀ  at a London 
NHS service94 also showed that workers underestimated 
the risk of HIV in people with schizophrenia. Although 
they reported feeling comfortable discussing sexual 
health, this rarely happened in practice.94 In addition, a 
qualitative study of Australian mental health nurses95 
showed that discussions of sex and sexuality were 
generally avoided.
In summary, we show the high prevalence of blood-
borne infections in people with serious mental illness, 
but more importantly we document the paucity of data 
on this topic. Although the physical health inequalities of 
people with serious mental illness have been identiﬁ ed 
and health policy is developing to ensure that these 
inequalities are addressed, little attention has been given 
to the sexual health and speciﬁ cally risk factors facilitating 
transmission of blood-borne viruses in people with 
serious mental illness in the UK and worldwide. There is 
an urgent need for further robust epidemiological 
research using representative samples of people with 
serious mental illness to assess the relationship between 
lifestyle behaviour and risk of infections to more fully 
understand the relationship between serious mental 
illness and viral infection, and to inform preventive 
strategies in this population.
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